The 73 references in paper G. NURULLINA M., G. AKHMADULLINA I., O. KRASNOPEROVA V., M. ALEKSEEVA M., O. ALEKSANDROVA V., A. CHERNOVA V., Г. НУРУЛЛИНА М., Г. АХМАДУЛЛИНА И., О. КРАСНОПЕРОВА В., М. АЛЕКСЕЕВА М., О. АЛЕКСАНДРОВА В., А. ЧЕРНОВА В. (2018) “ФАКТОРЫ РИСКА НИЗКОЭНЕРГЕТИЧЕСКИХ ПЕРЕЛОМОВ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА // RISK FACTORS OF LOW-ENERGY FRACTURES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS” / spz:neicon:ksma:y:2018:i:4:p:115-123

1
Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK,
(check this in PDF content)
2
08. 2. Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016; 7: 171-181. DOI: 10.5312/wjo.v7.i3.171
(check this in PDF content)
3
Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. и рабочая группа авторов. Фeдeрaльныe клиничecкиe рeкoмeндaции пo диaгнocтикe, лeчeнию и прoфилaктикe ocтeoпoрoзa. Проблемы эндокринологии. 2017; 63(6): 392-426. [Melnichenko GA, Belaya Zh. E., Rozhinskaya L. Ya. and a working group of authors. I. Federal clinical recommendations on diagnostics, treatment and prevention of osteoporosis. Problems of endocrinology. 2017; 63(6): 392-426. (In Russ.)]. DOI:10.14341/probl2017636392-426
(check this in PDF content)
4
Дедов И.И., Шестакова М.В., Майоров А.Ю. и рабочая группа авторов. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Москва: УП ПРИНТ, 2017. 112 с. [ Dedov II, Shestakova MV, Mayorov AYu and working group of authors. Algorithms of specialized medical care for patients with diabetes mellitus. The 8th issue. Moscow: UP Print, 2017. 112 p. (In Russ.)] DOI: 10.14341/DM20171S8
(check this in PDF content)
5
Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007; 18(4): 427-444. DOI: 10.1007/ s00198-006-0253-4
(check this in PDF content)
6
Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res. 2012; 27(11): 2231-2237. DOI: 10.1002/jbmr.1759
(check this in PDF content)
7
Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001; 86(1): 32-38. DOI: 10.1210/jcem.86.1.7139
(check this in PDF content)
8
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005; 48: 1292-1299. DOI: 10.1007/s00125-005-1786-3
(check this in PDF content)
9
Fraser LA, Pritchard J, Ioannidis G. Giangegorio LM, Adachi JD, Papaioannou A, Leslie WD. Clinical risk factors for fracture in diabetes: a matched cohort analysis. J Clin Densitom. 2011; 14(4): 416-421. DOI: 10.1016/j.jocd.2011.06.007
(check this in PDF content)
10
Ivers RQ, Cumming RG, Mitchell P, Peduto AJ, Blue Mountains Eye Study. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care. 2001; 24: 1198-1203.
(check this in PDF content)
11
Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008; 23: 1334-1342. DOI: 10.1359/jbmr.080323
(check this in PDF content)
12
Oei L, Zillikens MC, Dehghan A, Buitendijk GH, Castaño-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA, Hofman A, van Leeuwen JP, Witteman JC, Pols HA, Uitterlinden AG, Klaver CC, Franco OH, Rivadeneira F. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013; 36: 1619-1628. DOI: 10.2337/dc12-1188
(check this in PDF content)
13
Nielson CM, Marshall LM, Adams AL, LeBlanc ES, Cawthon PM, Ensrud K, Stefanick ML, Barrett-Connor E, Orwoll ES; Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the Osteoporotic Fractures in Men Study (MrOS). J Bone Miner Res. 2011; 26(3): 496-502. DOI: 10.1002/jbmr.235
(check this in PDF content)
14
Tanaka S, Kuroda T, Saito M, Shiraki M. Overweight/obesity and underweight are both risk factors for osteoporotic fractures at different sites in Japanese postmenopausal women. Osteoporos Int. 2013; 24(1): 69-76. DOI: 10.1007/s00198-012-2209-1
(check this in PDF content)
15
Neglia C, Argentiero A, Chitano G, Agnello N, Ciccarese R, Vigilanza A, Pantile V, Argentiero D, Quarta R, Rivezzi M1, Di Tanna GL, Di Somma C, Migliore A, Iolascon G, Gimigliano F, Distante A, Piscitelli P. Diabetes and obesity as independent risk factors for osteoporosis: updated results from the ROIS/EMEROS Registry in a population of five thousand Post-Menopausal women living in a region characterized by heavy environmental pressure. Int J Environ Res Public Health. 2016; 13(11): E1067. DOI: 10.3390/ ijerph13111067
(check this in PDF content)
16
Рымар О.Д., Полторацкая Е.С., Щербакова Л.В., Мустафина С. В., Малютина С. К. Факторы риска остеопоротических переломов у лиц 50-69 лет с сахарным диабетом и без нарушений углеводного обмена в популяции Новосибирска. Сборник тезисов VIII (XXV) Всероссийского диабетологический конгресс с международным участием «Сахарный диабет-пандемия XXI», 28 февраля-3 марта 2018 года. Москва: ООО «УП ПРИНТ», 2018. 457-458. [Rymar OD, Poltoratskaya ES, Shcherbakova LV, Mustafina SV, Malyutina SK. Risk factors of osteoporotic fractures in individuals aged 50-69 with diabetes mellitus and without violations of carbohydrate metabolism in population of Novosibirsk. Collection of theses of the VIII (XXV) All-Russian Diabetes Congress with international participation "Diabetes pandemic XXI", February
(check this in PDF content)
17
Рымар О.Д., Полторацкая Е.С., Щербакова Л.В., Мустафина С.В., Денисова Д.В., Вовак М., Малютина С.К. Факторы риска остеопоротических переломов с сахарным диабетом 50-69 лет в популяции Новосибирска. Материалы II Российской мультидисциплинарной конференции с международным участием «Сахарный диабет 2017: от мониторинга к управлению», г. Новосибирск, 19-20 апреля 2017. 123-126. [ Rymar OD, Poltoratskaya ES, Shcherbakova LV, Mustafina SV, Denisova DV, Vovak M., Malyutina SK. Risk factors for osteoporotic fractures with diabetes mellitus of 50-69 years in the population of Novosibirsk. Materials of the II Russian multidisciplinary conference with international participation "Diabetes mellitus 2017: from monitoring to management", Novosibirsk, 19-20 April 2017.
(check this in PDF content)
18
Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005; 165(14): 1612-1617. DOI: 10.1001/archinte.165.14.1612
(check this in PDF content)
19
Roman de Mettelinge T, Cambier D, Calders P, Van Den Noortgate N, Delbaere K. Understanding the relationship between type 2 diabetes mellitus and falls in older adults: a prospective cohort study. PLoS One. 2013; 8(6): e67055. DOI: 10.1371/journal. pone.0067055
(check this in PDF content)
20
Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications. 2006; 20(3): 158-162. DOI: 10.1016/j.jdiacomp.2005.06.004
(check this in PDF content)
21
Patel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int. 2008; 82(2): 87-91. DOI: 10.1007/ s00223-007-9082-5
(check this in PDF content)
22
Liefde II, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005; 16: 1713-1720. DOI: 10.1007/s00198-005-1909-1
(check this in PDF content)
23
Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care. 2005; 28(12): 2850-2855.
(check this in PDF content)
24
Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study. Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care. 2001; 24(7): 1198-1203.
(check this in PDF content)
25
Hsu JY, Cheng CY, Hsu CY. Type 2 diabetes mellitus severity correlates with risk of hip fracture in patients with osteoporosis. Neth J Med. 2018; 76(2): 65-71.
(check this in PDF content)
26
Josse RG, Majumdar SR, Zheng Y et al. Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. Diabetes Obes Metab. 2017; 19: 78-86.
(check this in PDF content)
27
Moayeri A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M. Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2017; 13: 455-468. DOI: 10.2147/TCRM.S131945.
(check this in PDF content)
28
Ruppert K, Cauley J, Lian Y, Zgibor JC, Derby C, Solomon DH. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study. Osteoporos Int. 2018; 29(2): 347-354. DOI: 10.1007/s00198-017-42769.
(check this in PDF content)
29
Wallander M, Axelsson KF, Nilsson AG, Lundh D, Lorentzon M. Type 2 Diabetes and Risk of Hip Fractures and Non-Skeletal Fall Injuries in the Elderly: A Study From the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO). J Bone Miner Res. 2017; 32(3): 449-460. DOI: 10.1002/jbmr.3002.
(check this in PDF content)
30
Rajpathak SN, Fu C, Brodovicz KG, Engel SS, Lapane K. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging. 2015; 32: 321-327. DOI: 10.1007/s40266-015-0254-0
(check this in PDF content)
31
Vianna AGD, de Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Borba VZC, Barreto FC. Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial. Diabetol Metab Syndr. 2017; 9(1): 35. DOI:10.1186/s13098-017-0232-2.
(check this in PDF content)
32
Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31(5): 845-851. DOI:10.2337/dc07-2270.
(check this in PDF content)
33
Gilbert MP, Pratley RE. The impact of diabetes and diabetes medications on bone health. Endocr Rev. 2015; 36(2): 194-213. DOI:10.1210/er.2012-1042.
(check this in PDF content)
34
Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009; 169(15): 1395-1402. DOI:10.1001/archinternmed.2009.214.
(check this in PDF content)
35
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008; 168(8): 820. DOI:10.1001/archinte.168.8.820.
(check this in PDF content)
36
Lecka-Czernik B. Safety of antidiabetic therapies on bone. Clin Rev Bone Min Metab. 2013; 11(1): 49-58. DOI:10.1007/ s12018-012-9129-7.
(check this in PDF content)
37
Kasai T, Bandow K, Suzuki H, Chiba N, Kakimoto K, Ohnishi T, Kawamoto S, Nagaoka E, Matsuguchi T. Osteoblast differentiation is functionally associated with decreased AMP kinase activity. J Cell Physiol. 2009; 221(3): 740-749. DOI:10.1002/jcp.21917.
(check this in PDF content)
38
Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem. 2011; 112(10): 2902-2909. DOI:10.1002/ jcb.23206.
(check this in PDF content)
39
Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE. 2015; 10(7): 1-15. DOI:10.1371/journal.pone.0132744.
(check this in PDF content)
40
Bunck MC, Eliasson B, Cornér A, Heine RJ, Shaginian RM, Taskinen MR, Yki-Järvinen H, Smith U, Diamant M. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13(4): 374-377. DOI:10.1111/j.1463-1326.2010.01355.x.
(check this in PDF content)
41
Li R, Xu W, Luo S, Xu H, Tong G, Zeng L, Zhu D, Weng J. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2015; 52(6): 1083-1091. DOI:10.1007/s00592-015-0792-2.
(check this in PDF content)
42
Su B, Sheng H, Zhang M, Bu L, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015; 48(1): 107-115. DOI:10.1007/s12020-014-0361-4.
(check this in PDF content)
43
Driessen JH, Henry RM, van Onzenoort HA, Lalmohamed A, Burden AM, Prieto-Alhambra D, Neef C, Leufkens HG, de Vries F. Bone fracture risk is not associated with the use of glucagon- like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. 2015; 97(2): 104-112. DOI:10.1007/s00223-015-9993-5.
(check this in PDF content)
44
Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Endocrinol Metab. 2007; 292(2): E543-548. DOI:10.1152/ajpendo.00364.2006.
(check this in PDF content)
45
Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A, Esbrit P, Valverde I, Villanueva-Peñacarrillo ML. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMPlinked GLP-1 receptor. J Cell Physiol. 2010; 225(2): 585-92. DOI:10.1002/jcp.22243.
(check this in PDF content)
46
Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res. 2005; 20(9): 1497-506. DOI:10.1359/JBMR.050524.
(check this in PDF content)
47
Xie D, Zhong Q, Ding K-H, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone. 2007; 40(5): 1352-60. DOI:10.1016/j.bone.2007.01.007.
(check this in PDF content)
48
Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016; 81(1): 78-88. DOI:10.1111/bcp.12777.
(check this in PDF content)
49
Bollag RJ, Zhong Q, Phillips P, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology. 2000; 141(3): 1228-1235. doi:10.1210/ endo.141.3.7366.
(check this in PDF content)
50
Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol. 2006; 20(7): 1644-1651. DOI:10.1210/ me.2005-0187.
(check this in PDF content)
51
Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 2008; 149(2): 574-579. DOI:10.1210/ en.2007-1292.
(check this in PDF content)
52
Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B, Liu J. Glucagon-like peptide-1 receptor agonist liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS ONE. 2015; 10(7): 1-15. DOI:10.1371/journal.pone.0132744.
(check this in PDF content)
53
Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011; 34(11): 2474-6. DOI:10.2337/dc11-1099.
(check this in PDF content)
54
Driessen JHM, van Onzenoort HAW, Henry RMA, Lalmohamed A, van den Bergh JP, Neef C, Leufkens HG, de Vries F. Use of dipeptidylpeptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture. Bone. 2014; 68: 124-130. DOI:10.1016/j. bone.2014.07.030.
(check this in PDF content)
55
Fu J, Zhu J, Hao Y, Guo C, Zhou Z. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep. 2016; 6(1): 29104. DOI:10.1038/ srep29104.
(check this in PDF content)
56
Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016; 101(1): 157-166. DOI:10.1210/jc.2015-3167
(check this in PDF content)
57
Vianna AGD, Sanches CP, Barreto FC. Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetology & Metabolic Syndrome. 2017; 9: 75. DOI:10.1186/s13098-0170274-5.
(check this in PDF content)
58
Mannucci E, Monami M. Bone fractures with sodium-glucose cotransporter-2 inhibitors: how real is the risk? Drug Saf. 2017; 40(2): 115-119. DOI:10.1007/s40264-016-0470-5.
(check this in PDF content)
59
Alba M, Xie J, Fung A, Desai M. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32(8): 1375-1385. DOI:10.1080/03007995.2016.1174 841.
(check this in PDF content)
60
Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2): 159-169. DOI:10.1111/dom.12189.
(check this in PDF content)
61
Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85(4): 962971. DOI:10.1038/ki.2013.356.
(check this in PDF content)
62
Ruanpeng D, Ungprasert P, Sangtian J, Harindhanavudhi T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2017; 33(6). DOI:10.1002/dmrr.2903.
(check this in PDF content)
63
Driessen JH, van Onzenoort HA, Starup-Linde J, Henry R, Burden AM, Neef C, van den Bergh JP, Vestergaard P, de Vries F. Use of glucagonlike-peptide 1 receptor agonists and risk of fracture as compared to use of other anti-hyperglycemic drugs. Calcif Tissue Int. 2015; 97(5): 506-515. DOI:10.1007/s00223-015-0037-y.
(check this in PDF content)
64
Tang HL, Li DD, Zhang JJ, Hsu YH, Wang TS, Zhai SD, Song YQ. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016; 18(12): 1199-1206. DOI:10.1111/dom.12742.
(check this in PDF content)
65
Raska I Jr, Raskova M, Zikan V, Škrha J. High prevalence of hypovitaminosis D in postmenopausal women with type 2 diabetes mellitus. Prague Med Rep. 2016; 117(1): 5-17.
(check this in PDF content)
66
Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, Meyer HE, Pfeifer M, Sanders KM, Stähelin HB, Theiler R, Dawson-Hughes B. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012; 367: 40-49. DOI: 10.1056/NEJMoa1109617
(check this in PDF content)
67
Seida JC, Mitri J, Colmers IN, Majumdar SR, Davidson MB, Edwards AL, Hanley DA, Pittas AG, Tjosvold L, Johnson JA. Clinical review: effect of vitamin D3 supplementation on improving glucose homeostasis and preventing diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014; 99(10): 35513560. DOI: 10.1210/jc.2014-2136
(check this in PDF content)
68
Yamauchi M, Kaji H, Nawata K, Takaoka S, Yamaguchi T, Sugimoto T. Role of parathyroid hormone in bone fragility of postmenopausal women with vitamin D insufficiency. Calcif Tissue Int. 2011; 88(5): 362-9. DOI: 10.1007/s00223-011-9464-6.
(check this in PDF content)
69
Seddek M, Shawky El-sayed M, El-Badawy A, Abd Elaal El Sha3er М. Study of relationship between type 2 diabetes mellitus and functional hypoparathyroidism. Int. J. Adv. Res. 2016; 4(11): 1088-1094. DOI: 10.21474/IJAR01/2187.
(check this in PDF content)
70
Thalassinos NC, Hadjiyanni P, Tzanela M, Alevizaki C, Philokiprou D. Calcium metabolism in diabetes mellitus: effect of improved blood glucose control. Diabet Med. 1993; 10(4): 341-4.
(check this in PDF content)
71
Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013; 56(2): 355-62. DOI: 10.1016/j.bone.2013.06.029.
(check this in PDF content)
72
Schacter GI, Leslie WD. DXA-based measurements in diabetes: can they predict fracture risk? Calcif Tissue Int. 2017; 100(2): 150-164. DOI: 10.1007/s00223-016-0191-x
(check this in PDF content)
73
Chung DJ, Choi HJ, Chung YS, Lim SK, Yang SO, Shin CS. The prevalence and risk factors of vertebral fractures in Korean patients with type 2 diabetes. J Bone Miner Metab. 2013; 31(2): 161-168. DOI: 10.1007/s00774-012-0398-5 Поступила / Received 16.05.2018
(check this in PDF content)